Doxorubicin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Doxorubicin

Examples of brand names: Caelyx pegylated liposomal [EU; pegylated liposomal formulation, not interchangeable with other doxorubicin forms]

ATC code: L01DB01

Main use (for orientation): Caelyx example: selected breast/ovarian cancers, multiple myeloma, AIDS-related Kaposi's sarcoma

Documented research summary

Historical small human pharmacokinetic investigation reports no apparent THC-related doxorubicin change, without modern equivalence assurance. Antiemetic studies heterogeneous, including a negative n=8 crossover. Numerous CBD transporter/tumour/organ-protection models, but no clinical CBD–doxorubicin safety confirmation. A cannabidiol/cannabidiolic-acid oil dog study is not transferable to humans.

Uncertainties and limitations

Intravenous liposomal DOXIL, not pharmacokinetically interchangeable with conventional doxorubicin. Literature predominantly conventional doxorubicin; preclinical effects are not a dosing basis.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

10 separately recorded findings. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0114

Type of result: Context-specific finding; read the limitations

Observation: CBD increased doxorubicin accumulation in transporter cell models.

Mechanism: P-glycoprotein transport inhibition

Study type: In-vitro transporter/cell assay

Context studied: CBD 5–100 µM, Caco-2/LLC-PK1-MDR1; doxorubicin as a transporter probe. Caco-2/LLC-PK1/MDR1 cells; micromolar CBD.

Clinical interpretation: Clinical effect unknown

Limitations and uncertainties: No evidence of stronger cancer treatment or greater patient toxicity. Laboratory maximum concentrations/expression; not a clinical AUC or toxicity prediction. THC/CBN did not show the same P-gp inhibition.

Original sources for this finding: Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana [ME05]

THC – clinically investigated

Finding ID: B0241

Type of result: Clinical, small historical pharmacokinetics

Observation: No apparent change in doxorubicin AUC with THC reported.

Mechanism: Historical human pharmacokinetics during chemotherapy

Study type: Human pharmacokinetics

Context studied: Doxorubicin/cyclophosphamide; high variability.

Clinical interpretation: Direct but weak pair evidence

Limitations and uncertainties: No modern equivalence assessment or CBD conclusion; not DOXIL-specific.

Original sources for this finding: Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. [BMED6271847]

Oral/smoked THC – clinically investigated

Finding ID: B0242

Type of result: Clinical, small controlled study

Observation: No significant antiemetic benefit over placebo in the n=8 crossover.

Mechanism: Antiemetic efficacy with doxorubicin plus cyclophosphamide

Study type: Double-blind crossover

Context studied: Sarcoma chemotherapy with doxorubicin plus cyclophosphamide.

Clinical interpretation: Negative antiemesis finding, not pharmacokinetic safety assurance

Limitations and uncertainties: Combination regimen; not an isolated doxorubicin interaction.

Original sources for this finding: A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. [BMED6261926]

THC – clinically investigated

Finding ID: B0243

Type of result: Clinical, historical

Observation: Historical studies reported antiemetic effects or comparability with haloperidol, with poorer THC tolerability.

Mechanism: Symptomatic antiemesis

Study type: Controlled antiemetic studies

Context studied: Mixed chemotherapies; Orr 1980/81: same 55 patients.

Clinical interpretation: Do not equate with altered chemotherapy exposure

Limitations and uncertainties: Older small studies; combinations; no CBD evidence.

Original sources for this finding: Comparative trial of the antiemetic effects of THC and haloperidol. [BMED6271838]; Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. [BMED6271846]; Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. [BMED6254456]

CBD + CBDA-containing hemp oil – laboratory and animal studies

Finding ID: B0244

Type of result: Animal/veterinary

Observation: No significant within-individual AUC change in the active arm; week-5 between-group difference with AUC increase in the placebo arm.

Mechanism: Doxorubicin pharmacokinetics during CHOP in dogs

Study type: Prospective randomised placebo-controlled

Context studied: 25 dogs enrolled, 19 completed 5 weeks.

Clinical interpretation: Not a human interaction prediction

Limitations and uncertainties: Small veterinary study; do not reinterpret different time/group comparisons as proven inhibition.

Original sources for this finding: Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy. [BMED40622742]

CBD – laboratory and animal studies

Finding ID: B0245

Type of result: Preclinical

Observation: Increased doxorubicin uptake/apoptosis or sensitivity in cell and some xenograft models.

Mechanism: TRPV2/chemosensitising tumour effect

Study type: Cell/animal models

Context studied: Hepatoma, glioma, breast cancer, osteosarcoma; different formulations.

Clinical interpretation: Experimental treatment finding

Limitations and uncertainties: Not clinical tumour-efficacy or safety evidence; a patient TRPV2-expression correlation is not a CBD-administration study.

Original sources for this finding: 2-APB and CBD-Mediated Targeting of Charged Cytotoxic Compounds Into Tumor Cells Suggests the Involvement of TRPV2 Channels. [BMED31680972]; TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. [BMED30323891]; Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. [BMED23079154]; Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45α, integrin-α5, -β5, -β1, and autophagy. [BMED35217991]; The synergistic anticancer effect of CBD and DOX in osteosarcoma. [BMED36848028]; Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models. [BMED34324983]

CBD + THCV – laboratory and animal studies

Finding ID: B0246

Type of result: Preclinical

Observation: Pretreatment increased chemosensitivity in 2D/3D and mouse models.

Mechanism: Alteration of epigenetic/histone signalling pathways in a doxorubicin-resistant tumour model

Study type: Cell/animal model

Context studied: Doxorubicin-resistant MDA-MB231.

Clinical interpretation: Experimental

Limitations and uncertainties: Not transferable to humans/other cannabinoids.

Original sources for this finding: The role of Cannabidiol and tetrahydrocannabivarin to overcome doxorubicin resistance in MDA-MB-231 xenografts in athymic nude mice. [BMED36535544]

CBD – laboratory and animal studies

Finding ID: B0247

Type of result: Preclinical

Observation: Animal models report cardiac, renal or neuropsychological protective signals; one study also reports CBD's own cardiotoxicity and no prevention of weight loss.

Mechanism: Organ-protection/inflammation signals with doxorubicin

Study type: Animal/cell models

Context studied: Various high doses, routes and chemotherapy combinations.

Clinical interpretation: No clinical protection recommendation

Limitations and uncertainties: Benefits not uniform; no clinical exposure/benefit confirmation.

Original sources for this finding: Cannabidiol Ameliorates Doxorubicin-Induced Myocardial Injury via Activating Hippo Pathway. [BMED39876987]; Improved Therapeutic Efficacy of Doxorubicin Chemotherapy With Cannabidiol in 4T1 Mice Breast Cancer Model. [BMED39503169]; Effects of Cannabidiol (CBD) on Doxorubicin-Induced Anxiety and Depression-like Behaviors and mRNA Expression of Inflammatory Markers in Rats. [BMED39452013]; Prospective affirmative therapeutics of cannabidiol oil mitigates doxorubicin-induced abnormalities in kidney function, inflammation, and renal tissue changes. [BMED37971510]; Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis. [BMED25569804]; Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. [BMED23721741]; Cannabidiol alleviates chemotherapy-induced cognitive decline and neuropathology. [BMED42202974]

THC – laboratory and animal studies

Finding ID: B0248

Type of result: Preclinical

Observation: Mice: less weight loss and longer small intestine, but no corresponding inflammatory gene-expression effects.

Mechanism: Intestinal injury/inflammation with doxorubicin

Study type: Mouse model

Context studied: Oral THC 10/20 mg/kg.

Clinical interpretation: Mixed/partly negative finding

Limitations and uncertainties: No clinical intestinal/colitis protection demonstrated.

Original sources for this finding: Delta-9-Tetrahydrocannabinol alleviates doxorubicin-induced weight loss but does not affect dextran sodium sulphate-induced colitis. [BMED41530821]

CBD – laboratory and animal studies

Finding ID: B0249

Type of result: Preclinical

Observation: Individual cell/formulation models report additive or synergistic CBD/doxorubicin effects; results heterogeneous. PMID33247539 describes doxorubicin less clearly; PMID41471054 confirms only CBD plus paclitaxel as both additive/synergistic and chemically compatible in the abstract summary.

Mechanism: Cytotoxic combination in veterinary tumour models or formulated delivery

Study type: Cell/formulation experiments

Context studied: Canine lymphoma models and formulated CBD/doxorubicin combinations.

Clinical interpretation: Experimental

Limitations and uncertainties: Do not infer patient safety or unchanged pharmacokinetics.

Original sources for this finding: Cytotoxicity of Cannabinoids in Combination with Traditional Lymphoma Chemotherapeutic Drugs Against Non-Hodgkin's Lymphoma. [BMED41595541]; The effect of cannabidiol on canine neoplastic cell proliferation and mitogen-activated protein kinase activation during autophagy and apoptosis. [BMED33247539]; Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms. [BMED34576262]; CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer. [BMED31811927]; From Screening to a Nanotechnological Platform: Cannabidiol-Chemotherapy Co-Loaded Lipid Nanocapsules for Glioblastoma Multiforme Treatment. [BMED41471054]

References and access status

[V2_LABEL_D0452] DOXIL (DOXORUBICIN HYDROCHLORIDE) INJECTION, SUSPENSION, LIPOSOMAL [BAXTER HEALTHCARE COMPANY]

Original source / bibliographic reference

Authors: Baxter Healthcare Company

Year: 2022

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[ME05] Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana

Original source / bibliographic reference

Authors: Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; Gefroh HA; DeVane CL

Year: 2006

Source type: Original study: transporter/cell assays

DOI: 10.1124/jpet.105.098541

PMID: 16439618

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[BMED40622742] Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy.

Original source / bibliographic reference

Authors: Lejeune A, Bechtel S, Milner R, Fagman L, Leal Yepes FA, Wakshlag JJ.

Year: 2025

Source type: Publication; title and abstract reviewed

DOI: 10.1111/jvim.70179

PMID: 40622742

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED36535544] The role of Cannabidiol and tetrahydrocannabivarin to overcome doxorubicin resistance in MDA-MB-231 xenografts in athymic nude mice.

Original source / bibliographic reference

Authors: Kalvala AK, Nimma R, Bagde A, Surapaneni SK, Patel N, Arthur P, Sun L, Singh R, Kommineni N, Nathani A, Li Y, Singh M.

Year: 2023

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.biochi.2022.12.008

PMID: 36535544

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED41530821] Delta-9-Tetrahydrocannabinol alleviates doxorubicin-induced weight loss but does not affect dextran sodium sulphate-induced colitis.

Original source / bibliographic reference

Authors: Johansen MW, Andersen MCE, Nissen T, Nexoe AB, Ünsal S, Madsen GI, Möller S, Kjeldsen J, Sorensen GL, Holmskov U, Husby S, Rathe M.

Year: 2026

Source type: Publication; title and abstract reviewed

DOI: 10.1186/s42238-026-00386-z

PMID: 41530821

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED39876987] Cannabidiol Ameliorates Doxorubicin-Induced Myocardial Injury via Activating Hippo Pathway.

Original source / bibliographic reference

Authors: Dong T, Li J, Liang X, Wang W, Chen M, Yang G, Wu D.

Year: 2025

Source type: Publication; title and abstract reviewed

DOI: 10.2147/dddt.s497323

PMID: 39876987

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED39503169] Improved Therapeutic Efficacy of Doxorubicin Chemotherapy With Cannabidiol in 4T1 Mice Breast Cancer Model.

Original source / bibliographic reference

Authors: Tabatabaei K, Moazzezi S, Emamgholizadeh M, Vaez H, Baradaran B, Shokouhi B.

Year: 2024

Source type: Publication; title and abstract reviewed

DOI: 10.1002/cam4.70395

PMID: 39503169

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED39452013] Effects of Cannabidiol (CBD) on Doxorubicin-Induced Anxiety and Depression-like Behaviors and mRNA Expression of Inflammatory Markers in Rats.

Original source / bibliographic reference

Authors: Poudel B, Bany BM, Hales DB, Cheatwood JL.

Year: 2024

Source type: Publication; title and abstract reviewed

DOI: 10.3390/brainsci14100999

PMID: 39452013

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED37971510] Prospective affirmative therapeutics of cannabidiol oil mitigates doxorubicin-induced abnormalities in kidney function, inflammation, and renal tissue changes.

Original source / bibliographic reference

Authors: Soliman NA, Dahmy SIE, Shalaby AA, Mohammed KA.

Year: 2024

Source type: Publication; title and abstract reviewed

DOI: 10.1007/s00210-023-02836-4

PMID: 37971510

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED36848028] The synergistic anticancer effect of CBD and DOX in osteosarcoma.

Original source / bibliographic reference

Authors: Li J, Jiang W, Shan W, Luo A, Qu G, Zhang J, Luo X, Xia J.

Year: 2023

Source type: Publication; title and abstract reviewed

DOI: 10.1007/s12094-023-03119-3

PMID: 36848028

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED34324983] Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models.

Original source / bibliographic reference

Authors: Patel N, Kommineni N, Surapaneni SK, Kalvala A, Yaun X, Gebeyehu A, Arthur P, Duke LC, York SB, Bagde A, Meckes DG, Singh M.

Year: 2021

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.ijpharm.2021.120943

PMID: 34324983

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED35217991] Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45α, integrin-α5, -β5, -β1, and autophagy.

Original source / bibliographic reference

Authors: Surapaneni SK, Patel N, Sun L, Kommineni N, Kalvala AK, Gebeyehu A, Arthur P, Duke LC, Nimma R, G Meckes D, Singh M.

Year: 2022

Source type: Publication; title and abstract reviewed

DOI: 10.1007/s13346-022-01137-2

PMID: 35217991

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED31680972] 2-APB and CBD-Mediated Targeting of Charged Cytotoxic Compounds Into Tumor Cells Suggests the Involvement of TRPV2 Channels.

Original source / bibliographic reference

Authors: Neumann-Raizel H, Shilo A, Lev S, Mogilevsky M, Katz B, Shneor D, Shaul YD, Leffler A, Gabizon A, Karni R, Honigman A, Binshtok AM.

Year: 2019

Source type: Publication; title and abstract reviewed

DOI: 10.3389/fphar.2019.01198

PMID: 31680972

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED30323891] TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer.

Original source / bibliographic reference

Authors: Elbaz M, Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser MW, Shilo K, Ganju RK.

Year: 2018

Source type: Publication; title and abstract reviewed

DOI: 10.18632/oncotarget.9663

PMID: 30323891

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED25569804] Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis.

Original source / bibliographic reference

Authors: Hao E, Mukhopadhyay P, Cao Z, Erdélyi K, Holovac E, Liaudet L, Lee WS, Haskó G, Mechoulam R, Pacher P.

Year: 2015

Source type: Publication; title and abstract reviewed

DOI: 10.2119/molmed.2014.00261

PMID: 25569804

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED23721741] Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity.

Original source / bibliographic reference

Authors: Fouad AA, Albuali WH, Al-Mulhim AS, Jresat I.

Year: 2013

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.etap.2013.04.018

PMID: 23721741

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED23079154] Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents.

Original source / bibliographic reference

Authors: Nabissi M, Morelli MB, Santoni M, Santoni G.

Year: 2013

Source type: Publication; title and abstract reviewed

DOI: 10.1093/carcin/bgs328

PMID: 23079154

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED6261926] A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.

Original source / bibliographic reference

Authors: Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Rosenberg SA.

Year: 1981

Source type: Publication; title and abstract reviewed

DOI: 10.1002/1097-0142(19810401)47:7<1746::aid-cncr2820470704>3.0.co;2-4

PMID: 6261926

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED6271838] Comparative trial of the antiemetic effects of THC and haloperidol.

Original source / bibliographic reference

Authors: Neidhart JA, Gagen MM, Wilson HE, Young DC.

Year: 1981

Source type: Publication; title and abstract reviewed

DOI: 10.1002/j.1552-4604.1981.tb02571.x

PMID: 6271838

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED6271847] Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin.

Original source / bibliographic reference

Authors: Riggs CE, Egorin MJ, Fuks JZ, Schnaper N, Duffey P, Colvin OM, Aisner J, Wiernik PH, Bachur NR.

Year: 1981

Source type: Publication; title and abstract reviewed

DOI: 10.1002/j.1552-4604.1981.tb02581.x

PMID: 6271847

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED6271846] Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine.

Original source / bibliographic reference

Authors: Orr LE, McKernan JF.

Year: 1981

Source type: Publication; title and abstract reviewed

DOI: 10.1002/j.1552-4604.1981.tb02578.x

PMID: 6271846

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED6254456] Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.

Original source / bibliographic reference

Authors: Orr LE, McKernan JF, Bloome B.

Year: 1980

Source type: Publication; title and abstract reviewed

DOI: 10.1001/archinte.140.11.1431

PMID: 6254456

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED42202974] Cannabidiol alleviates chemotherapy-induced cognitive decline and neuropathology.

Original source / bibliographic reference

Authors: Madan S, El-Khatib SM, Prathigudupu A, Avalos HC, Ahmed F, Piomelli D, Chan A, Gupta K, Jung KM, Acharya MM.

Year: 2026

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.canlet.2026.218612

PMID: 42202974

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED41595541] Cytotoxicity of Cannabinoids in Combination with Traditional Lymphoma Chemotherapeutic Drugs Against Non-Hodgkin's Lymphoma.

Original source / bibliographic reference

Authors: Omer S, Mansour M, Pondugula SR, Dhanasekaran M, Matz B, Khan O, Boothe D.

Year: 2025

Source type: Publication; title and abstract reviewed

DOI: 10.3390/biomedicines14010003

PMID: 41595541

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED33247539] The effect of cannabidiol on canine neoplastic cell proliferation and mitogen-activated protein kinase activation during autophagy and apoptosis.

Original source / bibliographic reference

Authors: Henry JG, Shoemaker G, Prieto JM, Hannon MB, Wakshlag JJ.

Year: 2021

Source type: Publication; title and abstract reviewed

DOI: 10.1111/vco.12669

PMID: 33247539

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED34576262] Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.

Original source / bibliographic reference

Authors: Alsherbiny MA, Bhuyan DJ, Low MN, Chang D, Li CG.

Year: 2021

Source type: Publication; title and abstract reviewed

DOI: 10.3390/ijms221810103

PMID: 34576262

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED31811927] CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer.

Original source / bibliographic reference

Authors: Fraguas-Sánchez AI, Fernández-Carballido A, Simancas-Herbada R, Martin-Sabroso C, Torres-Suárez AI.

Year: 2020

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.ijpharm.2019.118916

PMID: 31811927

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED41471054] From Screening to a Nanotechnological Platform: Cannabidiol-Chemotherapy Co-Loaded Lipid Nanocapsules for Glioblastoma Multiforme Treatment.

Original source / bibliographic reference

Authors: Gómez-Lázaro L, Aparicio-Blanco J, Fraguas-Sánchez AI, Montejo-Rubio MC, Martín-Sabroso C, Torres-Suárez AI.

Year: 2025

Source type: Publication; title and abstract reviewed

DOI: 10.3390/pharmaceutics17121537

PMID: 41471054

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility